The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|November 6, 2014
Cirrus Pharmaceuticals Adds cGMP Suite
Author(s)Pharmaceutical Technology Editors
Facility will provide manufacturing services for inhalation, liquids, topicals and oral solids dosage forms
Advertisement
Pharmaceutical contract development and manufacturing services provider Cirrus Pharmaceuticals, a Kemwell company, has announced that it will invest in a flexible cGMP suite in its facility in Research Triangle Park, NC. The addition of the suite will allow the company to offer cGMP manufacturing services for inhalation, liquids, topicals and oral solids dosage forms. The facility is scheduled to be operational in April 2015.
Kemwell’s R&D division employs 175 scientists worldwide and provides formulation development, analytical development, validation and clinical trial manufacturing.
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement